NZ590283A - Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors - Google Patents
Imidazolylpyrimidine compounds as hdac and / or cdk inhibitorsInfo
- Publication number
- NZ590283A NZ590283A NZ590283A NZ59028309A NZ590283A NZ 590283 A NZ590283 A NZ 590283A NZ 590283 A NZ590283 A NZ 590283A NZ 59028309 A NZ59028309 A NZ 59028309A NZ 590283 A NZ590283 A NZ 590283A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- fibrosis
- methylimidazol
- benzamide
- pyrimidin
- Prior art date
Links
- FKTSKGMJQQGFHN-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyrimidine Chemical class C1=CNC(C=2N=CC=CN=2)=N1 FKTSKGMJQQGFHN-UHFFFAOYSA-N 0.000 title abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 2
- 206010038389 Renal cancer Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 201000010982 kidney cancer Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 abstract 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000015634 Rectal Neoplasms Diseases 0.000 abstract 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 abstract 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 206010028537 myelofibrosis Diseases 0.000 abstract 1
- YMLQRYKINUKINE-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]-(2,2,2-trifluoroethyl)amino]benzamide Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(N(CC(F)(F)F)C=2C=CC(=CC=2)C(=O)NC=2C(=CC=CC=2)N)=N1 YMLQRYKINUKINE-UHFFFAOYSA-N 0.000 abstract 1
- FGBPHRIWQHJOSZ-UHFFFAOYSA-N n-(2-aminophenyl)-4-[ethyl-[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzamide Chemical compound N=1C=CC(C=2N(C(C)=NC=2)C(C)C)=NC=1N(CC)C(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N FGBPHRIWQHJOSZ-UHFFFAOYSA-N 0.000 abstract 1
- QLRQHJBGBSBLSA-UHFFFAOYSA-N n-(2-aminophenyl)-4-[methyl-[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzamide Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(N(C)C=2C=CC(=CC=2)C(=O)NC=2C(=CC=CC=2)N)=N1 QLRQHJBGBSBLSA-UHFFFAOYSA-N 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 206010038038 rectal cancer Diseases 0.000 abstract 1
- 201000001275 rectum cancer Diseases 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8042608P | 2008-07-14 | 2008-07-14 | |
| PCT/US2009/050558 WO2010009139A2 (en) | 2008-07-14 | 2009-07-14 | Imidazolyl pyrimidine inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ590283A true NZ590283A (en) | 2012-11-30 |
Family
ID=41061109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ590283A NZ590283A (en) | 2008-07-14 | 2009-07-14 | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8134000B2 (enExample) |
| JP (2) | JP5640005B2 (enExample) |
| AU (1) | AU2009271003A1 (enExample) |
| CA (1) | CA2729909A1 (enExample) |
| NZ (1) | NZ590283A (enExample) |
| WO (1) | WO2010009139A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090005374A1 (en) * | 2007-06-26 | 2009-01-01 | Melvin Jr Lawrence S | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| EP2303841A1 (en) * | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| NZ590283A (en) | 2008-07-14 | 2012-11-30 | Gilead Sciences Inc | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
| CA2731323A1 (en) * | 2008-07-28 | 2010-02-04 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
| CA2735158C (en) | 2008-08-29 | 2016-11-08 | Treventis Corporation | Compositions and methods of treating amyloid disease |
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| EP2440519A1 (en) * | 2009-06-08 | 2012-04-18 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| CA2763167A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| JP6250403B2 (ja) | 2011-02-28 | 2017-12-20 | バイオマリン ファーマシューティカル インク | ヒストン脱アセチル化酵素阻害剤 |
| JP6240063B2 (ja) | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート， インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| WO2013006408A1 (en) * | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2014018979A1 (en) | 2012-07-27 | 2014-01-30 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| JP6503338B2 (ja) | 2013-03-15 | 2019-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｈｄａｃ阻害剤 |
| TWI720269B (zh) * | 2016-11-22 | 2021-03-01 | 財團法人生物技術開發中心 | 用於調節刺蝟途徑之雜芳基胺化合物及其製法及用途 |
| MX2021011775A (es) | 2017-04-26 | 2023-01-10 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
| CN108929312A (zh) * | 2017-05-22 | 2018-12-04 | 南开大学 | 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂 |
| CN112135610A (zh) | 2018-01-12 | 2020-12-25 | KDAc治疗股份有限公司 | 用于治疗癌症的选择性组蛋白去乙酰酶3(hdac3)抑制剂及免疫治疗剂的组合 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| CN109761842B (zh) * | 2019-02-01 | 2021-11-30 | 浙江工业大学 | α-F-β-NHAc-羰基化合物的合成方法 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| BR112022002698A2 (pt) | 2019-08-14 | 2022-07-19 | Incyte Corp | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| CN114105958B (zh) * | 2021-12-03 | 2022-11-22 | 郑州大学第一附属医院 | 一组含羟肟酸的2-苯氨基嘧啶类衍生物及其应用 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| KR20240124952A (ko) | 2021-12-22 | 2024-08-19 | 어거스틴 테라퓨틱스 | Hdac6 억제제로서의 화합물 및 이의 용도 |
| WO2024261327A1 (en) * | 2023-06-21 | 2024-12-26 | Augustine Therapeutics | 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as hdac6 inhibitors |
| WO2024261328A1 (en) * | 2023-06-21 | 2024-12-26 | Augustine Therapeutics | Amide-amine compounds and use thereof as hdac6 inhibitors |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1209803A (zh) | 1996-01-16 | 1999-03-03 | 布里斯托尔-迈尔斯斯奎布公司 | 微粒体甘油三酯转移蛋白的构象限制性芳族抑制剂及方法 |
| US20040006011A1 (en) | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| EP1216228B1 (en) | 1999-09-17 | 2008-10-29 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| WO2001053331A2 (en) | 2000-01-24 | 2001-07-26 | Adherex Technologies, Inc. | Peptidomimetic modulators of cell adhesion |
| AU2001234689A1 (en) | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | Bivalent phenylene inhibitors of factor xa |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| CA2407573C (en) | 2000-04-27 | 2011-09-13 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US20040067938A1 (en) | 2000-09-29 | 2004-04-08 | Penglie Zhang | Quaternary amines and related inhibitors of factor xa |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| DE60230160D1 (de) | 2001-02-20 | 2009-01-15 | Astrazeneca Ab | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
| EP1383799A4 (en) | 2001-04-10 | 2008-08-06 | Transtech Pharma Inc | PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS |
| BR0210464A (pt) | 2001-06-21 | 2004-07-20 | Smithkline Beecham Corp | Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| EP1270551A1 (en) | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Urea derivatives with antiproteolytic activity |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| ES2262893T3 (es) | 2001-10-05 | 2006-12-01 | Smithkline Beecham Corporation | Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes. |
| AU2002352663B2 (en) | 2001-11-13 | 2007-06-21 | Axys Pharmaceuticals, Inc. | Cyanoalkylamino derivatives as protease inhibitors |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| JP2003313126A (ja) | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| US20040034084A1 (en) | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
| GB0212049D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| CA2388358A1 (en) | 2002-05-31 | 2003-11-30 | Voiceage Corporation | A method and device for multi-rate lattice vector quantization |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| US7282608B2 (en) | 2002-10-17 | 2007-10-16 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US20040087642A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| US20040092568A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
| CN1717396A (zh) | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途 |
| US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| WO2004076452A1 (en) | 2003-02-26 | 2004-09-10 | Merck Sharp & Dohme Limited | 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| CA2517427C (en) | 2003-03-06 | 2012-07-24 | Merck & Co., Inc. | Antiprotozoal imidazopyridine compounds |
| CN102304110A (zh) | 2003-04-07 | 2012-01-04 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
| CA2521915A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Alpha substituted carboxylic acid as ppar modulators |
| US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
| US20050234066A1 (en) | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
| US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| EP1663953A1 (en) | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| ES2436888T3 (es) | 2003-09-26 | 2014-01-07 | Exelixis, Inc | Moduladores c-Met y métodos de uso |
| EP1684690A4 (en) | 2003-11-06 | 2008-10-15 | Celgene Corp | METHODS OF USE AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS |
| US7524851B2 (en) | 2003-12-05 | 2009-04-28 | Robert Bosch Gesellschaft Fur Medizinische Forschung (Rbmf) | Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy |
| WO2005060571A2 (en) | 2003-12-10 | 2005-07-07 | Merck & Co., Inc. | Antiprotozoal imidazopyridine compounds |
| US7671181B2 (en) | 2004-01-16 | 2010-03-02 | Merck Sharp & Dohme Corp. | Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agents |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
| US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| KR101258504B1 (ko) | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| US20080146585A1 (en) | 2004-04-20 | 2008-06-19 | Ab Science | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy |
| WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
| JP4879165B2 (ja) | 2004-04-20 | 2012-02-22 | トランス テック ファーマ，インコーポレイテッド | メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体 |
| WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
| CA2564570A1 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating plasmodium related diseases |
| JP2007533732A (ja) | 2004-04-23 | 2007-11-22 | アブ サイエンス | 線維症を処置するためのｃ−ｋｉｔ阻害剤の使用法 |
| JP2007538064A (ja) | 2004-05-18 | 2007-12-27 | アブ サイエンス | 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法 |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| WO2006044509A2 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| KR20070086600A (ko) | 2004-11-23 | 2007-08-27 | 셀진 코포레이션 | Ｃｎｓ 손상의 치료를 위한 ｊｎｋ 억제제 |
| US20080125432A1 (en) | 2004-12-01 | 2008-05-29 | Devgen Nv | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family |
| US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| CA2594325A1 (en) | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | Condensed imidazole compound and use thereof |
| EP1841766A1 (en) | 2005-01-19 | 2007-10-10 | Biolipox AB | Pyrrolopyridines useful in the treatment of inflammation |
| GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| CA2603748A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| BRPI0608910A2 (pt) | 2005-05-09 | 2010-02-17 | Achillion Pharmaceuticals Inc | uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada |
| JP4528918B2 (ja) | 2005-06-21 | 2010-08-25 | 学校法人 関西大学 | カルボキサミド誘導体 |
| MA28394B1 (fr) | 2005-06-24 | 2007-01-02 | Genelabs Tech Inc | Derives d'heteroaryle pour traitement des virus |
| US7309787B2 (en) | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| EP1904065A2 (en) | 2005-07-14 | 2008-04-02 | AB Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| CA2621057A1 (en) | 2005-09-07 | 2007-03-15 | Laboratoires Serono S.A. | Ikk inhibitors for the treatment of endometriosis |
| EP1939175B1 (en) | 2005-09-27 | 2017-03-01 | Shionogi&Co., Ltd. | Sulfonamide derivative having pgd2 receptor antagonistic activity |
| CA2623374A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| ITMI20060296A1 (it) | 2006-02-17 | 2007-08-18 | Alberto Lodolo | Dispositivo di intercettazione multifunzionale |
| EP1996233A2 (en) | 2006-02-27 | 2008-12-03 | Gilead Colorado, Inc. | Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions |
| EP2013196B1 (en) | 2006-04-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| US20090005374A1 (en) | 2007-06-26 | 2009-01-01 | Melvin Jr Lawrence S | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| NZ590283A (en) | 2008-07-14 | 2012-11-30 | Gilead Sciences Inc | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
| AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| CA2731323A1 (en) | 2008-07-28 | 2010-02-04 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
| CA2763167A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds |
| EP2440519A1 (en) | 2009-06-08 | 2012-04-18 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
-
2009
- 2009-07-14 NZ NZ590283A patent/NZ590283A/xx not_active IP Right Cessation
- 2009-07-14 WO PCT/US2009/050558 patent/WO2010009139A2/en not_active Ceased
- 2009-07-14 CA CA2729909A patent/CA2729909A1/en not_active Abandoned
- 2009-07-14 AU AU2009271003A patent/AU2009271003A1/en not_active Abandoned
- 2009-07-14 US US12/502,870 patent/US8134000B2/en not_active Expired - Fee Related
- 2009-07-14 JP JP2011518843A patent/JP5640005B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-07 JP JP2014000744A patent/JP2014058583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8134000B2 (en) | 2012-03-13 |
| WO2010009139A3 (en) | 2010-07-08 |
| CA2729909A1 (en) | 2010-01-21 |
| US20100009990A1 (en) | 2010-01-14 |
| WO2010009139A2 (en) | 2010-01-21 |
| JP2014058583A (ja) | 2014-04-03 |
| AU2009271003A1 (en) | 2010-01-21 |
| JP2011528039A (ja) | 2011-11-10 |
| JP5640005B2 (ja) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ590283A (en) | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors | |
| NZ590320A (en) | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases | |
| Guo et al. | Discovery of pyrroloaminopyrazoles as novel PAK inhibitors | |
| Huynh et al. | Optimization of pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1) | |
| Breitenlechner et al. | Structure-based optimization of novel azepane derivatives as PKB inhibitors | |
| Buchholz et al. | The first potent inhibitors for human glutaminyl cyclase: Synthesis and structure− activity relationship | |
| WO2007149395A3 (en) | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer | |
| Davey et al. | Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors | |
| AU2011334173B2 (en) | Quinazoline carboxamide azetidines | |
| BR0311343A (pt) | Derivados de piridazina | |
| MX2010002938A (es) | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. | |
| TW200619218A (en) | Pyrimidines as PLK inhibitors | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| Muth et al. | Tri-and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3 | |
| WO2005113515A8 (de) | Pyrimidine als plk inhibitoren | |
| MX2011012353A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. | |
| ATE469154T1 (de) | Pyrazolopyrimidine als zellzyklus-kinasehemmer | |
| WO2008017361A3 (de) | 2-(heterocyclylbenzyl)-pyridazinonderivate | |
| TW200618800A (en) | Heterocyclic compounds | |
| EA200700711A1 (ru) | Производные бензимидазолуксусной кислоты, проявляющие антагонизм в отношении рецептора crth2, и их применение | |
| WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| Vasbinder et al. | Discovery and optimization of a novel series of potent mutant B-RafV600E selective kinase inhibitors | |
| Fischer et al. | Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity | |
| DE602007001893D1 (en) | Aryl-4-ethinylisoxazolderivate | |
| Jin et al. | Novel indoline-2, 3-dione derivatives as inhibitors of aminopeptidase N (APN) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 JUL 2016 BY COMPUTER PACKAGES INC Effective date: 20130726 |
|
| LAPS | Patent lapsed |